Endogenous ligand

DPP IV Inhibitor Millipore

dianabol methandienone cas no 72 63 9 molecular research

DPP IV Inhibitor Millipore

Key Documents

DPP IV Inhibitor

Synonym(s): DPP IV Inhibitor, Dipeptidyl peptidase 4 Inhibitor, Gliptins

Select a Size

Pack Size	SKU	Availability	Price
1 mL	DPP4	Estimated to ship TODAY	$79.40
10 mL	DPP4-010	Estimated to ship TODAY	$609.00

About This Item

UNSPSC Code: 41116012

NACRES: NC.07

eCl@ss: 32160405

DPP4

$79.40

Properties

form

solution

NCBI accession no.

NM_001935.3

UniProt accession no.

P27487

Quality Level

100

Gene Information

human ... DPP4(1803)

Compare Similar Items

This Item	D3822	416200	124011
DPP IV Inhibitor Quick View	Dipeptidyl Peptidase IV Inhibitor I Quick View	Dipeptidylpeptidase IV Inhibitor I Quick View	Akt Inhibitor IV Quick View
Gene Information human ... DPP4(1803)	Gene Information -	Gene Information -	Gene Information -
Quality Level 100	Quality Level 200	Quality Level 100	Quality Level 100
form solution	form solid	form amorphous solid	form solid
NCBI accession no. NM_001935.3	NCBI accession no. -	NCBI accession no. -	NCBI accession no. -
UniProt accession no. P27487	UniProt accession no. -	UniProt accession no. -	UniProt accession no. -

Description

General description

Dipeptidyl peptidase IV (DPP IV), a dimeric type II integral membrane glycoprotein, is a member of the family of prolyl-specific proteases. It is abundantly expressed in the epithelial and nonepithelial tissues. It is highly expressed in the kidney and the colon.

Application

Research Category All

Biochem/physiol Actions

Dipeptidyl peptidase IV (DPP IV) controls insulin-stimulating hormones, glucagon-like peptide (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP). It′s a promising therapeutic target for type 2 diabetes (T2DM). In addition to its catalytic action, DPP-4 also serves as a binding protein and a ligand of extracellular factors. DPP-4 inhibition causes GLP-1 and GIP to have a prolonged activity, hence DPP-4 inhibitors help maintain glucose homeostasis. DPP IV inhibitors can improve glycemic control for a longer period when compared to early oral hypoglycemics.